Ask Gilead to reduce the price of PrEP to support HIV prevention in Europe

The Issue

There are 373 people diagnosed with HIV every day in Europe, and many more who do not know that they have HIV. 

Current prevention options in Europe include abstinence, condoms, and monogamy. Better access to treatment for people living with HIV means that they are not infectious to others. But altogether these haven’t solved the problem and we still have a raging HIV epidemic in Europe and beyond.

There is a new tool we need to add to the prevention package – pre-exposure prophylaxis or PrEP for short. PrEP is for HIV negative people and involves taking a pill to stop them catching HIV (typically Truvada which is a pill used for treatment of HIV). Truvada has been licensed and recommended for people at risk of HIV in the United States since July 2012 and recent WHO guidelines recommend PrEP for those at risk of HIV. 

However, we still don’t have PrEP in Europe.

PrEP provides near perfect protection when taken during periods of risk – adding this to the prevention package has had a dramatic impact on HIV infection rates in San Francisco. 

Why hasn’t Europe got PrEP? 

Two major barriers are the lack of prevention infrastructure across Europe and the cost of the drug. Both of these require new investment by European governments at a time of constrained resources.

We want Gilead Sciences, the company that makes Truvada, to be a good partner for prevention and reduce the price of the drug.

You can help us by signing this petition!

 

 

 

avatar of the starter
EuroPrEPPetition Starter• Who are EuroPrEP? EuroPrEP started as clinicians and advocates working to prevent HIV throughout Europe, most of whom also provide care and support to people living with HIV and hepatitis C. • What does EuroPrEP want? To include pre-exposure prophylaxis (PrEP) in our national HIV prevention programmes. The most commonly used drug, Truvada, costs about 500 euros for a month when purchased from Gilead (more than 10 times what it costs to make it). • Why are we signing this petition? We want Gilead to be a good partner and reduce the price of drug when used for prevention. They will still make a profit, but reducing the price will help to persuade governments they can afford to invest in this new tool.
Media enquiries
This petition had 2,338 supporters

The Issue

There are 373 people diagnosed with HIV every day in Europe, and many more who do not know that they have HIV. 

Current prevention options in Europe include abstinence, condoms, and monogamy. Better access to treatment for people living with HIV means that they are not infectious to others. But altogether these haven’t solved the problem and we still have a raging HIV epidemic in Europe and beyond.

There is a new tool we need to add to the prevention package – pre-exposure prophylaxis or PrEP for short. PrEP is for HIV negative people and involves taking a pill to stop them catching HIV (typically Truvada which is a pill used for treatment of HIV). Truvada has been licensed and recommended for people at risk of HIV in the United States since July 2012 and recent WHO guidelines recommend PrEP for those at risk of HIV. 

However, we still don’t have PrEP in Europe.

PrEP provides near perfect protection when taken during periods of risk – adding this to the prevention package has had a dramatic impact on HIV infection rates in San Francisco. 

Why hasn’t Europe got PrEP? 

Two major barriers are the lack of prevention infrastructure across Europe and the cost of the drug. Both of these require new investment by European governments at a time of constrained resources.

We want Gilead Sciences, the company that makes Truvada, to be a good partner for prevention and reduce the price of the drug.

You can help us by signing this petition!

 

 

 

avatar of the starter
EuroPrEPPetition Starter• Who are EuroPrEP? EuroPrEP started as clinicians and advocates working to prevent HIV throughout Europe, most of whom also provide care and support to people living with HIV and hepatitis C. • What does EuroPrEP want? To include pre-exposure prophylaxis (PrEP) in our national HIV prevention programmes. The most commonly used drug, Truvada, costs about 500 euros for a month when purchased from Gilead (more than 10 times what it costs to make it). • Why are we signing this petition? We want Gilead to be a good partner and reduce the price of drug when used for prevention. They will still make a profit, but reducing the price will help to persuade governments they can afford to invest in this new tool.
Media enquiries

Petition Closed

This petition had 2,338 supporters

Share this petition

The Decision Makers

Gilead Sciences
Gilead Sciences
Petition updates
Share this petition
Petition created on 30 November 2015